论文部分内容阅读
腺病毒载体相对于其他基因载体具有转导效率高,宿主范围广的优点,广泛应用于癌症的基因治疗中。临床试验已证明腺病毒瘤内注射可有效治疗原发性肿瘤,但难以满足静脉注射治疗转移性肿瘤的需求。传统的腺病毒静脉注射后易被肝脾细胞摄取,存在体内免疫原性强、血液半衰期短、肿瘤靶向性差的问题。采用聚合物或纳米材料对腺病毒进行表面修饰,构建腺病毒纳米复合物,是解决以上问题的新方法。本文综述了用于静脉注射治疗癌症的腺病毒纳米复合物的研究进展。
Compared with other gene vectors, adenovirus vectors have the advantages of high transduction efficiency and wide host range, and are widely used in the gene therapy of cancer. Clinical trials have proved that adenovirus intratumoral injection can effectively treat primary tumors, but difficult to meet the needs of intravenous treatment of metastatic tumors. Traditional adenovirus is easily taken up by liver and spleen cells after intravenous injection, which has the problems of strong immunogenicity, short blood half-life and poor tumor targeting in vivo. Adopting polymer or nanomaterials to surface modification of adenovirus and constructing adenovirus nanocomposite is a new method to solve the above problems. This article reviews the research progress of adenovirus nanocomposites for intravenous treatment of cancer.